Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bushen Quhan Zhiwang Decoction for Deep Remission in Rheumatoid Arthritis
NCT06309030Not yet recruiting
- Start
- Apr 2024
- Primary completion
- Dec 2025
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
01
Overview
Randomised, double-blind trial of bushen quhan zhiwang decoction in rheumatoid arthritis (RA) (2 arms). Primary endpoint: Disease Activity Score 28 at 16 weeks. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
bushen quhan zhiwang decoction
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06309030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06309030.